Clinique Research Development Limited

The 2nd Principal Investigators’ Forum is just 3 days away.
Click the link below👇🏽to register and be a part of the forum.
https://lnkd.in/daPVGawd

Upon registration, you will receive a confirmation mail and login details to the virtual forum.

Share with a colleague today!

The Principal Investigators’ Forum is just 9 days away
Click the link below👇🏽to register and be a part of the forum.
https://us06web.zoom.us/meeting/register/tZAkcOmrqT4tG9eGuHnZSLEHMmaC3Yqki8MN

Upon registration, you will receive a confirmation mail and login details to the virtual forum.

Share with a colleague today!

Clinique Research cordially invites you to the second edition of the Principal Investigators’ Forum scheduled to hold on Thursday, 15th September 2022.
The forum will enable P*s across Africa meet to share successes, challenges, learn practical clinical approaches, network, and lots more. Taking a prominent part in this forum will aid in improving collaborations across sites in Africa.

To make inquiries about the forum, send a mail to [email protected]

Together we will make Africa the destination point for quality clinical research.

*s

Clinique Research cordially invites Principal Investigators to the inaugural Principal Investigators Forum slated to take place on June 15, 2022.

The forum will bring together Principal Investigators from across Africa to share their accomplishments and challenges, learn practical clinical research strategies, network and much more.

To register, kindly send the following details to; [email protected]
Full name
Mobile number
Email address
Job Description
Organization
Experience in clinical trials

Registration is free!

Understanding the safety and efficacy of innovative medicines across demographic subgroups, which is critical for reducing inequities and improving equity, is hampered by a lack of diversity.
Clinique Research, West Africa's leading indigenous CRO, fills this void by providing clinical trial monitoring and regulatory services to a wide range of sponsors and CROs across the continent.
This allows pharmaceutical companies to develop medicines for which we can be more confident that the outcomes will apply to everyone who will take those medicines in the future.

Every year on May 20, International Clinical Trials Day commemorates the start of the first randomized clinical trials by James Lind in 1747.

Are you a Principal Investigator or medical professional interested in the field of clinical research? Would like to make your clinical research site visible and attractive?

Join us for our first Investigators meet-up, a forum for African research sites to network, exchange ideas, and collaborate.

This quarterly event will provide a fresh and valuable chance to engage in conversations of mutual interest, including updates on current developments and sharing of best practices.

To sign up; send a mail to [email protected]

Happy New Year!

Welcome to 2022!

Clinique Research wishes you a prosperous year!

#2022

Clinique is delighted to announce TCIS AFRICA's 3rd annual summit!
Africa's largest and most anticipated clinical research summit of the year. TCIS AFRICA a converging point for clinical researchers, medical professionals, CROs, pharmaceutical companies, regulatory agencies, and academia to network, share accomplishments, milestones, and challenges, and set strategic direction for clinical trial management in Africa.
See you there!!!

For registration, kindly visit www.tcisafricang.com

Follow Africa on Facebook for more updates.


#


IS READY

Administrative Assistant
•
Send your CV to [email protected]
Must reside on the island.

Clinical Trial Assistant
•
Send your CV to [email protected]
Must reside on the Island

The VP, Clinical and Regulatory Affairs, 54gene; Kemi Williams is a strategic and results-driven biotechnology leader with over 19 years combined experience in the pharmaceutical, medical device and diagnostics industries.
•
She graced our last event and gave a lecture on “The value and challenges of genetics-based clinical trials”.
•
The chart shows a slide from her presentation. Check out ‘TCIS AFRICA DAY 2’ on Youtube for the full lecture.
•

At the last summit, Ms. Mthombeni, chairperson of South African Clinical Research Association (SACRA) spoke on South Africa’s contribution, challenges and successes in clinical trials in Africa.
•
She attributed the high number of clinical trials conducted in South Africa to good infrastructure and sufficient number of Principal Investigators with great expertise.
•
With Nigeria’s rank on the displayed chart, what do you think are the limiting factors to conducting a higher number of clinical trials.
•
As you highlight them in the comment section below, kindly include possible solutions.
•
We can do better, we will!

Margaret Williams, a speaker at the Clinical Investigators’ Summit is a Senior Clinical Research Associate and Chief Executive Officer of Margan Clinical Research Organization (MMARCRO).

She received her MPH degree from the University of Ghana, Legon (2007), and her CRA graduate certification from the Michener Institute for Applied Health Sciences, Canada (2011) and also has extensive post graduate training in Research Ethics and Good Clinical Practice.

She has worked as a Contract Clinical Research Associate for the Swiss Tropical and Public Health Institute, (Swiss TPH) in Basel, Switzerland, Agence Africaine de Recherché en Santé Humaine (AARSH) and Santé Plus in Dakar Senegal and Kendle Services in South Africa.

Her experience in phase I to IV clinical trials co-ordination and monitoring since 2007 has involved clinical research in a variety of infectious diseases including rotavirus diseases, meningitis, tuberculosis and malaria.
Her vision to provide meticulous clinical trial monitoring in both Anglophone and Francophone countries enabled the strategic partnership between her and her Associate Dr. Elizabeth Diallo.

Dr. Halima Bello-Manga, a speaker at the second edition of the Clinical Investigators’ Summit, obtained her medical degree from ABU Zaria, MBBS (ABU, Zaria), an MPH from the University of Liverpool, UK. She went on to complete her specialist training in Haematology (FMCPath) from the National Postgraduate Medical of Nigeria, NPMCN and is currently a Senior Lecturer and Consultant at Kaduna State University and Barau Dikko Teaching Hospital, Kaduna.

She was a recipient of the American Society of Hematology’s Visitor Training Program (ASH VTP) in 2016 and spent some time at the Vanderbilt University Medical Center learning about conducting research in sickle cell disease.

She is a Vanderbilt Institute Research Development and Ethics Scholar (VIRDE) and more recently in 2019, she was among the 20 junior faculty selected to participate in the prestigious American Society of Hematology’s Clinical Research Training Institute (ASH CRTI), a year-long program focused on clinical research and career development.

She was the site investigator for the recently completed NIH-funded randomized control SPRING trial.

As a recipient of the Emerging Global Leader Award (K43) which supports early-career research scientists from low to middle-income countries,

Dr. Bello-Manga is the Principal Investigator for the project, “Primary Prevention of Stroke in Children with Sickle Cell Anaemia in Nigeria: Community vs Teaching Hospital,” funded by the NIH Fogarty International Center and National Institute of Neurological disorders and Stroke (NINDS).
-manga

Clinique Research is excited to announce that BWICR (Black Women in Clinical Research) USA will be giving away BWICR calendars to the first 10 women to follow BWICR Facebook and LinkedIn pages and post

will be attending TCIS AFRICA 2021!

Thank you BWICR👏🏼👏🏼👏🏼

FACT: Participating in a clinical trial is always voluntary. You have the right to leave the study at any time, for any reason without any penalty.

Pfizer Inc and BioNTech SE today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease.

Based on current projections, Pfizer expects to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Source: Pfizer

~Zora Neale Hurston

Will you like to be a sponsor of our 2nd Annual Clinical Investigators’ Summit?
•
Will you like to partner with us in raising the bar of clinical trials in Africa?
•
Kindly send a mail to [email protected]
•
We look forward to having you on board.

Israel administered the first dose of its Covid-19 vaccine as the first phase of its clinical trials began on Sunday at Sheba Medical Center near Tel Aviv.

The first dose was given to 26-year-old volunteer Segev Harel, who will now be monitored for three weeks, to see if he has any side effects and whether he develops antibodies.

The vaccine, which is called BriLife -- a combination of the Hebrew words for health, Israel, and life -- was developed at the Israel Institute for Biological Research (IIBR).

As part of Phase 1 trials, either the vaccine or a placebo will be administered to 80 volunteers between the ages of 18 and 55 at two different hospitals in Israel.

We have been working around the clock leading up to this important day -- the start of clinical trials," said Dr. Shmuel Yithzaki, the head of the Biology Division at the IIBR. "The work of all the hidden heroes in the institute and the hospitals has been poured into a little bottle which has the potential to bring a life-saving vaccine to the citizens of the state of Israel."
The second phase, expected to begin in December, will see 960 healthy volunteers given the vaccine or a placebo. This phase will involve safety tests on the vaccine, to determine the effective dosage, and further examine the vaccine’s effectiveness.

The third phase, expected to begin in April or May 2021, will see more widespread testing with the participation of 30,000 volunteers.

"The true exit from the coronavirus crisis is in the development of vaccines," said Prime Minister Benjamin Netanyahu after visiting the hospital. "Therefore, this is a very important day, a day that gives a shot of encouragement."

Source: CNN

FACT: Clinical trials are designed for research purposes and as a result, some level of risk is involved.

However, investigational drugs are given to clinical trial participants only after the drugs have gone through a rigorous testing process and scientific evidence indicates that the drug is likely to be effective and safe for use in humans.

In addition, keeping you safe when you volunteer to participate in a clinical trial is a top priority for everyone involved in the trial. All clinical trials are reviewed before they start by an institutional review board (IRB), a committee made up of doctors, scientists and community members who have the responsibility to protect clinical trial participants.

During clinical trials, participants’ safety is frequently assessed and monitored by the researchers.

Nigeria, Guinea, SierraLeone, Liberia remain the epicenters of Lassa Fever in Africa.
Lassa Fever is an acute viral haemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses.

Humans usually become infected with Lassa virus through exposure to food or household items contaminated with urine or faeces of infected Mastomys rats. The disease is endemic in the rodent population in parts of West Africa.

About 80% of people who become infected with Lassa virus have no symptoms. 1 in 5 infections result in severe disease, where the virus affects several organs such as the liver, spleen and kidneys.

Candidate drugs are in early stages of testing and vaccines are in development.

Source: World Health Organisation.

Are you a Principal Investigator?
Join us at Clinique Research; simply click on the link in our bio to sign up.
Forward all enquires to [email protected]

Prof. Alash’le Abimiku obtained her doctorate degree in Medical Microbiology from the London School of Hygiene and Tropical Medicine in 1988.
Her career for over 30 years has distinguished her as an academic, scientist and researcher who has blazed the trail in promoting quality laboratory medicine practices in Nigeria and Africa.
In 1993, her post-doctoral research was the first to document the unique HIV strain prevalent in Nigeria as HIV subtype G. She also established the first reliable HIV research laboratory in Central Nigeria.
Prof. Abimiku has published well over 70 peer-reviewed journal articles.

We pray for peace over Nigeria.
•
May the souls of the departed rest in peace.